Rigel Pharmaceuticals, Inc. (RIGL) Financials

RIGL Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 117.2 million 145.9 million
2023-09-30 115.3 million 147.2 million
2023-06-30 117.1 million 145.2 million
2023-03-31 123.6 million 147.9 million

RIGL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -6.4 million 1.9 million
2023-09-30 -1.4 million 1.9 million
2023-06-30 5.9 million 2.2 million
2023-03-31 -19.1 million 2.8 million

RIGL Net Income

No data available :(

RIGL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 56.9 million - 977000
2023-09-30 62.4 million - 1.1 million
2023-06-30 64.4 million 59.6 million 1.1 million
2023-03-31 58.7 million 59.5 million 1.3 million

RIGL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 174.5 million
2023-09-30 174.4 million
2023-06-30 173.7 million
2023-03-31 173.6 million

RIGL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 110000 3.2 million 26.9 million -
2023-09-30 22000 6.5 million 24.9 million -
2023-06-30 - 4.8 million 26.3 million -
2023-03-31 15.0 million 10.1 million 27.7 million -

RIGL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 35.8 million 3.8 million
2023-09-30 28.1 million 1.3 million
2023-06-30 26.9 million 1.1 million
2023-03-31 26.1 million 977000

RIGL

Price: $1.22

52 week price:
0.71
1.96

Payout Ratio Range:
-73.88%
-17.74%

Earnings Per Share: -0.14 USD

P/E Ratio: -8.71

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 2.8 million

Ebitda: -17.7 million

Market Capitalization: 214.0 million

Links: